Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P140-1MG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CNTF Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: AFTEHSPLTP HRRDLCSRSI WLARKIRSDL TALTQSYVKH QGLNKNINLD SADGMPVAST DQWSQLTQAQ RLQQNLQAYR TFHVLLARLL QDQQVHFTPT QGDFHQAIHT LLLQVAAFAY QIQQLMILLQ YKIPRNQADG MPINVGDGGL FQKKLWGLKV LQQLSQWTVR SIHDLRFISS HQTGIPARGS HYIANNKKM. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human CNTF. Anti-Human CNTF-specific antibody was purified by affinity chromatography employing an immobilized Human CNTF matrix. Sandwich ELISA: To detect Human CNTF by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human CNTF (500-P140Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human CNTF. Western Blot: To detect Human CNTF by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human CNTF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 1 mg
- Concentration
- 0.1-1.0 mg/mL
- Storage
- -20°C
Submitted references Non-cell autonomous promotion of astrogenesis at late embryonic stages by constitutive YAP activation.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Han D, Kwon M, Lee SM, Pleasure SJ, Yoon K
Scientific reports 2020 Apr 27;10(1):7041
Scientific reports 2020 Apr 27;10(1):7041
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ
Brain : a journal of neurology 2010 Aug;133(Pt 8):2232-47
Brain : a journal of neurology 2010 Aug;133(Pt 8):2232-47
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human CNTF by Western Blot analysis CNTF Polyclonal Antibody (Product # 500-P140-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human CNTF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human CNTF by Western Blot analysis CNTF Polyclonal Antibody (Product # 500-P140-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human CNTF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human CNTF by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of CNTF Polyclonal Antibody (Product # 500-P140-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech CNTF Polyclonal Antibody, Biotin (Product # 500-P140BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human CNTF.
